Action CPMV MOSAIC IMMUNOENGINEERING, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Mosaic ImmunoEngineering, Inc.

Actions

CPMV

US61945M1018

Marché Fermé - OTC Markets
Autres places de cotation
 16:50:17 01/05/2024 		Varia. 5j. Varia. 1 janv.
0,6 USD +1,90% Graphique intraday de Mosaic ImmunoEngineering, Inc. +91,63% 0,00%
19/04 Mosaic Immunoengineering, Inc. annonce le décès de Gloria Felcyn, administratrice indépendante et membre du comité d'audit, du comité de rémunération et du comité de gouvernance d'entreprise et de nomination CI
15/04 Mosaic ImmunoEngineering, Inc. annonce ses résultats pour l'exercice clos le 31 décembre 2023 CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Oncotelic Therapeutics, Inc. to Sell Its Necroptosis Cancer Therapy Assets to Mosaic ImmunoEngineering, Inc.
Mosaic Immunoengineering, Inc. Announces Demise of Gloria Felcyn, Independent Director and Member of Audit Committee, Compensation Committee and Corporate Governance and Nominating Committee
Mosaic ImmunoEngineering, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Mosaic ImmunoEngineering : Termination of Material Agreement - Form 8-K
Mosaic ImmunoEngineering, Inc. Receives Letter of Termination from CWRU
Mosaic ImmunoEngineering, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Mosaic ImmunoEngineering, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Mosaic ImmunoEngineering, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
MOSAIC IMMUNOENGINEERING INC. : Change in Directors or Principal Officers (form 8-K)
Mosaic Immunoengineering, Inc. Announces Nicole Steinmetz, Ph.D., to Resign as A Member of the Board of Directors and Acting Chief Scientific Officer
MOSAIC IMMUNOENGINEERING INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)
Mosaic ImmunoEngineering Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
Mosaic ImmunoEngineering Inc. Auditor Raises 'Going Concern' Doubt
MOSAIC IMMUNOENGINEERING INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
Mosaic ImmunoEngineering Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
Mosaic ImmunoEngineering Inc. Academic Collaborators Receives Grants Totaling $4.3 Million from NCI Focuses on its Novel Immuno-Oncology Platform
MOSAIC IMMUNOENGINEERING INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
Mosaic ImmunoEngineering Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
MOSAIC IMMUNOENGINEERING INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)
MOSAIC IMMUNOENGINEERING INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action CPMV
  4. Actualités Mosaic ImmunoEngineering, Inc.
  5. Autres langues